Key result
Dexmedetomidine (≥10 nM) induced a negative chronotropic effect on guinea pig sinoatrial node cells by downregulating the If current through imidazoline I1 receptors rather than α2-adrenoreceptors.
Why the study?
Dexmedetomidine is associated with an increased incidence of bradycardia, but the precise mechanism underlying this effect has not been fully elucidated.
Does dexmedetomidine reduce pacemaker activity in sinoatrial node cells through imidazoline receptors?
Does dexmedetomidine reduce pacemaker activity in sinoatrial node cells through imidazoline receptors?
Dexmedetomidine induces bradycardia by downregulating the hyperpolarization-activated cation current (If) in the sinoatrial node via imidazoline I1 receptors, rather than α2-adrenoreceptors.
May explain dexmedetomidine bradycardia in guinea pigs; hypothesis-generating for human I1-If effects, no practice change yet.
Dexmedetomidine (DEX), an α2-adrenoreceptor (α2-AR) and imidazoline receptor agonist, is most often used for the sedation of patients in the intensive care unit. Its administration is associated with an increased incidence of bradycardia; however, the precise mechanism of DEX-induced bradycardia has yet to be fully elucidated. This study was undertaken to examine whether DEX modifies pacemaker activity and the underlying ionic channel function through α2-AR and imidazoline receptors. The whole-cell patch-clamp techniques were used to record action potentials and related ionic currents of sinoatrial node cells in guinea pigs. DEX (≥10 nM) reduced sinoatrial node automaticity and the diastolic depolarization rate. DEX reduced the amplitude of hyperpolarization-activated cation current (If or Ih) the pacemaker current, even within the physiological pacemaker potential range. DEX slowed the If current activation kinetics and caused a significant shift in the voltage dependence of channel activation to negative potentials. In addition, efaroxan, an α2-AR and imidazoline I1 receptor antagonist, attenuated the inhibitory effects of DEX on sinoatrial node automaticity and If current activity, whereas yohimbine, an α2-AR-selective antagonist, did not. DEX did not affect the current activities of other channels, including rapidly and slowly activating delayed rectifier K+ currents (IKr and IKs), L-type Ca2+ current (ICa,L), Na+/Ca2+ exchange current (INCX), and muscarinic K+ current (IK,ACh). Our results indicate that DEX, at clinically relevant concentrations, induced a negative chronotropic effect on the sinoatrial node function through the downregulation of If current through an imidazoline I1 receptor other than the α2-AR in the clinical setting.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question. Dexmedetomidine was evaluated on Sinoatrial node automaticity and If current activity. Dexmedetomidine (≥10 nM) induced a negative chronotropic effect on guinea pig sinoatrial node cells by downregulating the If current through imidazoline I1 receptors rather than α2-adrenoreceptors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: